NCT02456701View on ClinicalTrials.gov

Enhancing Radioiodine Incorporation Into BRAF Mutant Thyroid Cancers With the Combination of Vemurafenib and KTN3379

PHASE1CompletedINTERVENTIONAL
Enrollment

7

Participants

Timeline

Start Date

June 30, 2015

Primary Completion Date

October 13, 2016

Study Completion Date

October 13, 2016

Conditions
Thyroid Cancer
Interventions
BIOLOGICAL

KTN3379

IV every 2 weeks

DRUG

vemurafenib

960 mg po bid

Trial Locations (1)

10065

Memorial Sloan-Kettering Cancer Center, New York

Sponsors
All Listed Sponsors
collaborator

Memorial Sloan Kettering Cancer Center

OTHER

lead

Celldex Therapeutics

INDUSTRY

NCT02456701 - Enhancing Radioiodine Incorporation Into BRAF Mutant Thyroid Cancers With the Combination of Vemurafenib and KTN3379 | Biotech Hunter | Biotech Hunter